Niimura, Takahiro Tokushima University
Zamami, Yoshito Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Hamano, Hirofumi Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ishida, Shunsuke Tokushima University
Goda, Mitsuhiro Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Takechi, Kenshi Tokushima University Tokushima University Educator and Researcher Directory
Chuma, Masayuki Tokushima University
Imanishi, Masaki Tokushima University
impaired glucose metabolism
spontaneous reporting system
Breakpoint cluster region‐Abelson murine leukemia (BCR‐ABL) inhibitors markedly improve the prognosis of chronic myeloid leukemia. However, high treatment adherence is necessary for successful treatment with BCR‐ABL inhibitors. Therefore, an adequate understanding of the adverse event profiles of BCR‐ABL inhibitors is essential. Although many adverse events are observed in trials, an accurate identification of adverse events based only on clinical trial results is difficult because of strict entry criteria or limited follow‐up durations. In particular, BCR‐ABL inhibitor‐induced impaired glucose metabolism remains controversial. Pharmacovigilance evaluations using spontaneous reporting systems are useful for analyzing drug‐related adverse events in clinical settings. Therefore, we conducted signal detection analyses for BCR‐ABL inhibitor‐induced impaired glucose metabolism by using the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) database. Signals for an increased reporting rate of impaired glucose metabolism were detected only for nilotinib use, whereas these signals were not detected for other BCR‐ABL inhibitors. Subgroup analyses showed a clearly increased nilotinib‐associated reporting rate of impaired glucose metabolism in male and younger patients. Although FAERS‐ and JADER‐based signal detection analyses cannot determine causality perfectly, our study suggests the effects on glucose metabolism are different between BCR‐ABL inhibitors and provides useful information for the selection of appropriate BCR‐ABL inhibitors.
John Wiley & Sons
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
cam_8_1_174.pdf 191 KB